CLEC4C (US20150299325A1 Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA855470MB1HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:CLEC4C重組單克隆抗體(US20150299325A1 Biosimilar Antibody)是一種針對(duì)C型凝集素結(jié)構(gòu)域家族4成員C(CLEC4C),其別名為血液樹(shù)突狀細(xì)胞抗原2(BDCA-2)、C型凝集素超家族成員7、樹(shù)突狀凝集素或CD303等,在免疫調(diào)控領(lǐng)域具有重要研究?jī)r(jià)值。該抗體以重組人CLEC4C蛋白制備,具有高度的種屬反應(yīng)性,專門針對(duì)人源CLEC4C靶點(diǎn),為相關(guān)研究提供了特異性工具。 針對(duì)CLEC4C抗體,US20150299325A1的類似物可通過(guò)調(diào)控其介導(dǎo)的信號(hào)通路發(fā)揮治療作用。CLEC4C作為樹(shù)突狀細(xì)胞表面的關(guān)鍵標(biāo)志物,在漿細(xì)胞樣樹(shù)突狀細(xì)胞(pDCs)表面高表達(dá),其信號(hào)通路參與免疫細(xì)胞的活化與增殖過(guò)程,并影響I型干擾素的分泌,與自身免疫性疾?。ㄈ缦到y(tǒng)性紅斑狼瘡)、病毒感染及腫瘤免疫逃逸密切相關(guān)。因此,以CLEC4C為靶點(diǎn)類似物可通過(guò)阻斷相關(guān)信號(hào)通路調(diào)節(jié)免疫應(yīng)答,為免疫失調(diào)疾病的臨床治療提供新策略。 該抗體為CLEC4C相關(guān)機(jī)制研究提供了重要手段。借助其特異性結(jié)合能力,研究人員可通過(guò)技術(shù)鑒定和分離pDCs,深入探究CLEC4C在免疫激活、抗原呈遞中的作用機(jī)制。此外,在藥物研發(fā)階段,該抗體可用于評(píng)估候選藥物對(duì)CLEC4C靶點(diǎn)的結(jié)合活性及特異性,驗(yàn)證藥物的靶向性和有效性,加速相關(guān)治療方案的轉(zhuǎn)化應(yīng)用。其高度的種屬特異性也確保了在人源細(xì)胞或組織模型中的研究可靠性,推動(dòng)免疫學(xué)基礎(chǔ)研究與臨床應(yīng)用的銜接。
-
Uniprot No.:
-
基因名:
-
別名:C-type lectin domain family 4 member C;Blood dendritic cell antigen 2;BDCA-2;C-type lectin superfamily member 7;Dendritic lectin;CD antigen CD303, CLEC4C, BDCA2 CLECSF11 CLECSF7 DLEC HECL
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human CLEC4C protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說(shuō)明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:In stock
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.
-
基因功能參考文獻(xiàn):
- Identification of serum glycoprotein ligands for the immunomodulatory receptor blood dendritic cell antigen 2. PMID: 29796630
- decrease in the surface expression of CLEC4C and the endoplasmic reticulum localization of the mutant construct were observed PMID: 26943047
- Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. PMID: 25779340
- BDCA-2 binds selectively to glycans containing the epitope Galbeta1-3/4GlcNAcbeta1-2Man. PMID: 25995448
- We show the crystal structures of a carbohydrate recognition domain (CRD) of human C-type lectin receptor blood dendritic cell antigen-2 (BDCA2). PMID: 24425442
- Reduction in Treg numbers following Ag delivery to BDCA2 restored both CD4(+) T cell activation and Ab responses, demonstrating that Tregs were required for the observed tolerance. PMID: 24829416
- Data show that HCV envelope glycoprotein E2 is a novel ligand of blood dendritic cells antigen 2 (BDCA-2). PMID: 23053572
- Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. PMID: 21880719
- Accumulation of BDCA-1 and BDCA-2 around neovessels showed that mDCs and pDCs are recruited to advanced arteriosclerotic plaques. PMID: 21436634
- Expression of dendritic cell markers CD11c/BDCA-1 and CD123/BDCA-2 in coronary artery disease upon activation in whole blood. PMID: 20888334
- Indoleamine 2,3-deoxigenase positive plasmacytoid dentritic cells are the classical BDCA2 positive cells in melanoma lymph nodes PMID: 19829303
- Data suggest that by associating with Fc epsilon RI gamma, BDCA2 activates a novel BCR-like signaling pathway to regulate the immune functions of plasmacytoid dendritic cells. PMID: 17850179
- Triggering CD303 leads to tyrosine phosphorylation of Syk, Slp65, PLCgamma2 and cytoskeletal proteins. CD303 signaling is linked with internalization by clathrin-mediated endocytosis. PMID: 18022864
- results suggest that downregulation of BDCA2 expression on plasmacytoid dendritic cells (pDCs) may reflect the activation of pDCs accumulated in systemic lupus erythematosus patients & may be one marker for indication of disease activity of SLE patients PMID: 18684674
- Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. PMID: 19577819
顯示更多
收起更多
-
亞細(xì)胞定位:Cell membrane; Single-pass type II membrane protein.
-
組織特異性:Expressed in plasmacytoid dendritic cells (PDCs). Constitutively expressed in immature monocyte-derived dendritic cells (iMDDC) and is significantly down-regulated upon maturation with LPS but not with TNF-alpha.
-
數(shù)據(jù)庫(kù)鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















